Reach 50% enrollment of the TMB-001 Phase 2B trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Feb 2021
- Due
- 31 Mar 2021
- Delivered
- 15 Mar 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Reach 50% enrollment of the Phase 2B trial”
What we found
Evidence strength A What the grades mean
The company announced on March 15, 2021, that it had reached 50% enrollment for the TMB-001 Phase 2b clinical trial, meeting the commitment before the end of the first quarter of 2021.
-
A Timber Pharmaceuticals, Inc. 10-Q filed 2021-05-11
“On March 15, 2021, we announced that 50% of patients in the Phase 2b clinical trial have been enrolled.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Reach
- Deliverable
- TMB-001 Phase 2B trial enrollment
- Target
- 50 percent
- In the company’s control
- High
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Timber Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C504167-023117 · Corrections policy